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SUPPLEMENTARY	PROTOCOL:	DETAILED	ARTIFICIAL	THYMIC	ORGANOID	(ATO)	METHOD	
	
REAGENTS		
	
CD34+	HSPC	isolation		
Fresh	human	umbilical	 cord	blood	 (CB),	bone	marrow	 (BM),	mobilized	peripheral	blood	 (MPB),	peripheral	blood	
(PB),	or	thymus	samples	
PBS	(Cellgro,	Cat.	21-031CV)	
Ficoll-Paque	(GE	Healthcare	Life	Sciences,	Cat.	17-1440-03)	
CD34	MicroBead	UltraPure	kit	(Miltenyi,	Cat.	130-100-453)	
Bovine	serum	albumin	(BSA)	Fraction	V,	30%	solution	(Gemini	Bio-Products,	Cat.	700-110)	
EDTA	(0.5	M)	pH	8.0	(Thermo	Fisher	Scientific,	Cat.	AM9260G)	
Mouse	anti-human	CD34	antibody,	clone	581	(Biolegend)	
Mouse	anti-human	CD3	antibody,	clone	UCHT1	(Biolegend)	
DAPI	(Thermo	Fisher	Scientific,	Cat.	D1306)	
	
MS5-hDLL1	cultures	
Dulbecco's	Modification	of	Eagle's	Medium	(DMEM)	(Cellgro,	Cat.	10-017-CV)	
Fetal	bovine	serum	(FBS)	(Gemini,	Cat.	900-208)	
Trypsin-EDTA	(0.25%)	(Thermo	Fisher	Scientific,	Cat.	25-300-054)	
	
ATOs	
RPMI	1640	(CellGro,		Cat.		10-040-CV)	
B-27	Supplement	(50X)	(Thermo	Fisher	Scientific,	Cat.		17504-044)		
GlutaMAX	Supplement	(100X)	(Thermo	Fisher	Scientific,	Cat.		35050-061)		
Penicillin/streptomycin	solution	(Gemini	Bio-Products,	Cat.		400-109)	
Ascorbic	acid	(L-Ascorbic	acid	2-phosphate	sesquimagnesium	salt	hydrate)	(Sigma-Aldrich,	Cat.		A8960)	
Recombinant	human	IL-7	(Peprotech,		Cat.		200-07)	
Recombinant	human	FLT3L	(Peprotech,	Cat.		300-19)	
	
EQUIPMENT	
	
CD34+	cell	isolation	
MACS	LS	columns	(Miltenyi,	Cat.	130-042-401)	
MidiMACS,	QuadroMACS,	or	autoMACS	cell	separator	(Miltenyi)	
15	mL	and	50	mL	conical	tubes	
Swinging-bucket	centrifuge	
FACS	sorter	
	
MS5-hDLL1	cultures	
Incubator,	humidified	at	37°C,	5%	CO2	
Tissue	culture	treated	T75	or	T150	culture	flasks	
15	mL	or	50	mL	conical	tubes	
	
ATO	cultures	
Millicell	cell	culture	inserts	(0.4	μm,	30mm	diameter)	(Millipore,	Cat.	PICM0RG50)	
6	well	tissue	culture	plates		
1.7	mL	microcentrifuge	tubes	
Micropipettes	(Rainin	P-20,	P-200,	P-1000)	
Micropipette	tips	
Small	blunt-end	tweezers	
70	μm	“Falcon”	cell	strainers	to	fit	50	mL	tubes	(Corning,	Cat.	352350)	
50	μm	cell	strainers	to	fit	15	mL	tubes	(Celltrics,	Cat.	04-004-2327)	
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15	mL	and	50	mL	conical	tubes	
Glass	pipettes	
Vacuum	aspirator	flask	
Swinging-bucket	centrifuge	with	FACs	tube	holders	
Incubator,	humidified	at	37°C,	with	5%	CO2	
	
	
PROCEDURE		
	
A. Preparation	of	ATO	complete	medium:		
	
1. Prepare	R-B27	medium	by	supplementing	RPMI	1640	with:	
- 4%	B-27	
- 30	μM	ascorbic	acid		
- 1X	penicillin/streptomycin		
- 1X	GlutaMAX	
	
Notes:		
- R-B27	as	described	above	 is	stable	 for	approximately	2	weeks	at	4°C.	Using	media	beyond	2	weeks	
may	adversely	affect	T	cell	differentiation.			
- Ascorbic	 acid	 powder	 is	 first	 dissolved	 in	 PBS	 to	make	 a	 30	mM	 (1000X)	 stock	 solution.	 This	 stock	
solution	can	be	stored	at	4°C	for	up	to	2	days,	however	we	recommend	using	freshly	made	ascorbic	
acid	solution	each	time	when	making	R-B27	medium.		
	
2. Complete	ATO	medium	by	freshly	adding	rhIL-7	(5	ng/mL)	and	rhFLT3L	(5	ng/mL)	to	a	working	volume	of	
R-B27.	
	
Notes:		
- Lyophilized	cytokines	are	reconstituted	in	sterile	PBS/0.1%	BSA	at	50	μg/mL,	and	stored	as	20-50	μL	
aliquots	at	-80°C.	Once	thawed,	aliquots	are	stored	at		4°C	for	up	to	10	days.	
- We	recommend	making	ATO	complete	medium	by	adding	cytokines	to	the	required	volume	of	R-B27	
before	each	use.	We	do	not	recommend	storing	cytokine-supplemented	medium	for	future	use.	
	
B. Isolation	of	CD34+	HSPCs		
	
1. Make	 single	 cell	 suspensions	 from	CB,	 BM,	MPB,	 or	 PB	 by	 diluting	 samples	 4X	with	 sterile	 PBS.	 Isolate	
mononuclear	cells	(MNCs)	by	Ficoll-Paque	gradient	centrifugation	as	per	manufacturer	instructions.	(This	
step	is	not	required	for	thymic	samples).		
2. Proceed	 to	CD34+	enrichment	of	MNCs	using	 the	CD34	MicroBead	UltraPure	 kit	 and	magnetic-assisted	
cell	sorting	(MACS)	(Miltenyi)	following	the	manufacturer’s	instructions.	
3. Stain	 the	 eluted	 CD34+	 positive	 fraction	with	 anti-CD34	 and	 anti-CD3	 antibodies	 and	DAPI,	 and	 isolate	
CD34+CD3-	cells	by	fluorescence-activated	cell	sorting	(FACS).		
4. Resuspend	the	purified	cells	in	R-B27	complete	medium	at	between	1-2x105	cells/mL.		
5. Keep	the	cells	on	ice	until	the	generation	of	ATOs.	
	
Notes:		
- FACS	 purification	 using	 anti-CD34	 and	 anti-CD3	 antibodies	 is	 highly	 recommended	 to	 remove	
contaminating	mature	T	cells,	which	will	proliferate	in	ATOs	and	may	lead	to	misinterpretation	of	 in	
vitro	T	cell	differentiation	data.		
- MACS-enriched	 CD34+	 cells	 from	 the	 different	 sources	 can	 be	 cryopreserved	 after	 magnetic	
separation	 in	 FBS/10%	 DMSA	 and	 stored	 in	 liquid	 nitrogen.	 When	 cells	 are	 needed,	 they	 can	 be	
thawed	 and	 resuspended	 in	 MACS	 buffer	 (PBS/0.5%	 BSA/2	 mM	 EDTA)	 before	 proceeding	 to	
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CD34+CD3-	 purification	 by	 FACS	 as	 above.	 We	 do	 not	 recommend	 cryopreserving	 whole	 MNC	
fractions	prior	to	CD34	enrichment	by	MACS.			
- If	 lentivirus-transduced	CD34+	cells	are	 required	 for	use	 in	ATOs,	proceed	 to	 lentiviral	 transduction	
immediately	 after	 FACS	 purification	 step.	 We	 typically	 activate	 HSPCs	 for	 12-18h,	 followed	 by	
transduction	 for	 24h,	 before	using	 in	ATOs.	 Transduced	 cells	 should	be	harvested,	washed	 at	 least	
twice	to	remove	free	viral	particles,	and	resuspended	in	R-B27	complete	medium	as	above.	
	
C. Maintenance	and	expansion	of	MS5-hDLL1	cells	
	
1. Maintain	and	expand	MS5-hDLL1	cells	in	standard	T75	or	T150	tissue	culture-treated	flasks	in	DMEM/10%	
FBS,	passaging	 them	 twice	a	week	by	 trypsinization	 for	 5	min.	 at	 37°C	when	 cells	 are	between	70-90%	
confluent.	Splitting	cells	for	passaging	is	typically	done	at	a	1:10	cells:media	ratio.	Cells	are	cultured	in	a	
standard	cell	incubator,	humidified	at	37°C,	with	5%	CO2.	
	
2. Scale	up	MS5-hDLL1	cells	for	each	ATO	experiment	by	plating	in	multiple	T75	or	T150	flasks	depending	on	
cell	number	required.	Cells	should	ideally	be	plated	at	least	2	days	before	each	ATO	experiment	to	allow	
for	>24h	between	trypsin	treatments.	Ideally	the	cells	should	be	between	70-90%	confluent	on	the	day	of	
use	in	ATOs.	
	
3. When	 generating	 ATOs,	 harvest	 MS5-hDLL1	 cells	 using	 trypsin	 and	 quenching	 with	 DMEM/10%	 FBS.	
Pipette	cells	gently	to	create	a	single	cell	suspension,	and	pass	through	a	70	μm	strainer	if	clumps	are	still	
visible.		Resuspend	cells	in	R-B27	complete	medium	and	count.	Keep	cells	on	ice	until	generation	of	ATOs.	
	
D. Generation	of	ATOs		
	
1. Prepare	 the	 required	number	of	6-well	 culture	plates	by	adding	1	mL	of	ATO	complete	medium	 (R-B27	
complete	medium	+	cytokines)	to	each	well.		
	
2. Using	tweezers,	transfer	a	cell	insert	into	each	well.	Only	the	bottom	of	the	insert	membrane	should	be	in	
contact	with	the	medium.	Set	aside	in	the	tissue	culture	hood	until	use.	
	
Combine	the	required	number	of	isolated	CD34+CD3-	cells	and	MS5-hDLL1	cells	and	in	a	microcentrifuge	
tube.	 We	 recommend	 combining	 enough	 cells	 for	 up	 to	 12	 ATOs	 per	 tube.	 We	 have	 found	 a	 1:20	
HSPC:stromal	cell	ratio	with	low	starting	cell	numbers	(e.g.	7500	CD34+CD3-	cells	and	1.5x105	MS5-hDLL1	
cells	per	ATO)	gave	optimal	expansion	and	maturation	of	T	cells	using	CB	CD34+CD3-	cells.		
	
3. Centrifuge	the	cells	at	300	g	for	5	min.	using	a	swinging-bucket	centrifuge	(1.5	and	1.7	mL	microcentrifuge	
tubes	fit	into	the	top	of	standard	5	mL	FACS	tube	centrifuge	buckets).	
	
Notes:	
- A	swinging-bucket	centrifuge	is	essential	for	this	step	to	ensure	the	cell	pellet	forms	at	the	bottom	of	
the	tube.	Use	of	a	standard	fixed-angle	rotor	microcentrifuge	is	not	recommended.	
	
4. Remove	the	supernatant	carefully	by	aspiration	using	a	vacuum	flask	and	glass	pipette.		
	
5. Resuspend	the	cell	pellet	by	briefly	vortexing	the	tube	on	low	to	medium	speed	using	short	pulses.		
	
6. Adjust	the	volume	of	the	cell	slurry	to	~5	μL	per	ATO	with	complete	R-B27.			
	
Notes:	
- Cell	slurry	is	very	thick,	to	avoid	cell	loss	from	cells	sticking	to	the	sides	of	the	pipette	tip,	coat	the	tip	
by	pipetting	medium	up	and	down	before	pipetting	the	cells.		
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- Because	 of	 the	 thickness	 of	 the	 cell	 slurry,	 the	 step	 of	 adjusting	 the	 volume	 can	 be	 challenging.	 If	
combining	 cells	 for	 12	 ATOs	 in	 a	 tube;	 after	 centrifugation,	 removal	 of	 the	 supernatant,	 and	
vortexing,	we	recommend	adding	10	μL	of	ATO	complete	medium	and	mixing	the	cell	pellet	by	gently	
pipetting.	It	is	then	easier	to	measure	the	exact	volume	with	a	pipette	and	to	add	enough	medium	to	
obtain	a	final	volume	of	60	μL	(5	μL	per	ATO).		
	
7. Using	 tweezers,	 remove	a	cell	 insert	 from	media	and	place	on	 the	edge	of	 the	well	 to	allow	 it	 to	drain	
slightly	immediately	before	plating	ATO.		
	
8. Draw	up	5	μL	of	the	cell	slurry	for	a	single	ATO	using	a	10	or	20	μL	pipette	tip	and		
gently	release	the	cell	slurry	as	a	drop	at	the	end	of	the	tip.	Gently	touch	the	drop	to	the	middle	of	the	cell	
insert	membrane	 to	 release	 it.	The	cell	 slurry	will	make	a	 small	 sphere	on	 the	surface	of	 the	cell	 insert	
(supplemental	protocol	Figure	1b).	
	
Notes:	
- If	multiple	ATOs	are	plated	to	increase	T	cell	yield,	up	to	2	ATOs	can	be	placed	on	a	single	cell	culture	
insert,	separated	by	approximately	1	cm	and	as	close	to	the	center	of	the	insert	as	possible.	We	do	
not	recommend	more	than	2	ATOs	per	insert,	as	T	cell	differentiation	may	be	adversely	affected.	
	
9. Using	tweezers,	gently	place	the	cell	insert	back	in	the	medium-containing	well.	Medium	should	never	be	
directly	in	contact	with	the	upper	surface	of	the	cell	organoid	(supplemental	protocol	Figure	1c).		
	
10. Once	all	ATOs	 for	one	plate	 are	generated,	 replace	 the	 lid	of	 the	plate	 and	place	 in	 a	 cell	 incubator	 at	
37°C,	5%	CO2	(supplemental	protocol	Figure	1c).		
 
	
Supp.	 Protocol	 Fig.	 1:	 	 a)	
Schematic	 of	 the	 ATO	
system.	 b)	 Generation	 of	
ATOs.	 Top	 row:	 deploying	
cell	 slurry	 on	 cell	 culture	
insert	 membrane.	 Bottom	
row:	returning	cell	insert	to	
well	 containing	 medium,	
and	 appearance	 of	 a	
completed	ATO.	
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E. Media	change	procedure	for	ATOs	
	
- ATO	 complete	medium	 (R-B27	 complete	medium	 +	 cytokines	 )	 is	 changed	 every	 3-4	 days.	 During	 this	
process,	the	ATO	should	never	be	disrupted.		
	
1. Tilt	 the	plate	 to	pool	media	on	one	 side	of	 the	well,	 being	 careful	not	 to	 let	media	overflow	on	 to	 the	
surface	of	the	cell	insert.		
2. Using	a	glass	pipette	attached	to	a	vacuum	aspirator,	aspirate	medium	from	around	the	cell	insert.	Leave	
~100-200	μL	of	medium	underneath	the	cell	insert	to	prevent	it	from	drying.	
3. Using	a	P-1000	and	1	mL	tip,	add	1	mL	of	fresh,	warm	ATO	complete	medium	between	the	cell	insert	and	
the	side	of	the	well,	allowing	it	to	spread	under	the	cell	insert	without	being	directly	in	contact	with	the	
ATO.		
	
F. Harvesting	cells	from	ATOs	
	
- Cells	can	be	harvested	at	any	time	point	 from	ATOs.	 If	 large	numbers	of	T	cells	are	required,	cells	 from	
multiple	ATOs	can	be	harvested	and	pooled.			
	
1. Using	a	P-1000,	add	1	mL	of	cold	MACS	buffer	 (PBS/0.5%	BSA/2mM	EDTA)	on	to	the	surface	of	 the	cell	
culture	insert,	immersing	the	ATO	
2. Pipette	up	and	down	several	times	to	detach	the	ATO	from	the	insert	membrane	and	mechanically	disrupt	
the	 organoid,	 being	 careful	 not	 to	 generate	 excessive	 air	 bubbles.	Hematopoietic	 cells	will	 be	 released	
into	the	medium	and	solid	“tissue”	debris	containing	mostly	stromal	cell	elements	will	not	be	disrupted	by	
pipetting.		
3. Transfer	the	cell	suspension	to	a	conical	tube	and	pass	through	a	cell	strainer	to	remove	debris.		
4. Wash	 the	 cell	 insert	 and	well	 3-4	 times	with	 cold	MACS	 buffer	 and	 transfer	 all	 washes	 to	 the	 original	
collection	tube.	
5. Spin	 cells	 down	 at	 300	 g	 for	 5	 minutes	 at	 4°C,	 and	 resuspend	 in	 desired	 medium	 for	 downstream	
applications.		
	
Notes:	
- If	 large	 numbers	 of	 ATOs	 are	 harvested	 at	 the	 same	 time,	 a	 1.8	 cm	 (blade	 length)	 soft	 blade	 cell	
scraper	can	be	used	to	rapidly	detach	ATOs	from	cell	culture	insert	membranes	while	submerged	in	3-
4	mL	cold	MACS	buffer.	Cell	 inserts	should	be	rinsed,	and	detached	ATOs	pipetted	up	and	down	as	
above	to	form	a	single	cell	suspension	before	passage	through	a	cell	strainer.	
- If	 cell	 analysis	 at	 multiple	 time	 points	 is	 needed,	 individual	 ATOs	 should	 be	 generated	 for	 each	
timepoint.	 The	 efficiency	 and	 feasibility	 of	 reaggregating	 cells	 harvested	 from	 ATOs	 has	 not	 been	
tested	and	is	not	recommended.		
	
TROUBLESHOOTING	
- D6.	
Problem:	Too	much	medium	is	left	after	aspiration	and	the	cell	volume	per	ATO	is	higher	than	8	μL.	
Solution:	Centrifuge	the	cells	again	and	remove	as	much	medium	as	possible	to	be	able	to	adjust	it	to	the	
right	volume.		
	
- D8.	
- Problem:	The	drop	of	cells	spreads	on	the	membrane	instead	of	creating	a	semi-sphere.	Possible	reason:	
The	concentration	of	cells	is	too	low	or	the	volume	is	too	high.	Solution:	Make	sure	the	concentration	of	
the	cells	is	accurate,	and	ensure	final	volume	is	5-6	μL	per	ATO.		
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Notes:	
- The	ATOs	will	tend	to	flatten	once	placed	into	the	incubator.	As	the	cells	proliferate	over	the	first	
2	weeks,	the	ATOs	will	grow	and	acquire	a	flattened	dome	shape.		
	
- E2.	
Problem:	The	totality	of	the	medium	is	aspirated	during	medium	change.	
Solution:	The	membrane	won’t	dry	instantly,	so	just	quickly	add	back	1	mL	of	fresh	medium	to	the	bottom	
of	the	well,	and	ensure	it	spreads	evenly	below	the	insert	membrane.	
	
- E3.	
Problem:	Media	falls	onto	the	membrane	surface	or	onto	the	ATO	during	medium	change.	
Solution:	ATOs	are	quite	stable.	With	a	glass	pipette	and	vacuum,	gently	aspirate	the	medium	from	the	
surface	of	the	cell	insert.		
	
TIME	REQUIRED	
	
CD34+	HSPC	isolation:	
- Variable	depending	on	 the	 type	and	number	of	 samples	but	 is	usually	 about	2	hours	 for	 the	 combined	
Ficoll	and	MACS	steps.	
- FACS	purification	of	CD34+	cells	usually	takes	2	hours	(including	antibody	staining	and	cell	sorting).	Thus,	
the	 preparation	 of	 HSPCs	 can	 be	 accomplished	 in	 4	 hours	 (or	 only	 2	 hours	 if	 the	 CD34+	 cells	 were	
previously	enriched	by	MACS	and	frozen).		
MS5-hDLL1	preparation:	
- Harvesting	 MS5-hDLL1	 cells	 for	 ATOs	 usually	 takes	 between	 30	 minutes	 to	 1	 hour,	 depending	 of	 the	
number	of	flasks	used,	and	can	be	done	while	the	HSPCs	are	being	isolated.		
ATO	generation:	
- Once	 HSPCs	 and	 MS5-hDLL1	 cells	 are	 harvested	 and	 counted,	 the	 time	 required	 to	 generate	 ATOs	 is	
variable	depending	on	the	number	created,	the	number	of	different	conditions,	and	the	experience	of	the	
investigator.	An	experienced	investigator	can	plate	~100	ATOs	in	1	hour.	
- The	whole	procedure	can	usually	be	accomplished	in	4	to	6	hours	for	large	ATO	experiments.		
	
ANTICIPATED	RESULTS		
	
Appearance	of	ATOs:		
- ATOs	will	usually	flatten	right	after	being	created	but	will	grow	back	to	a	flattened	dome		shape	as	the	
hematopoietic	cells	proliferate	over	the	first	2	weeks.		
- After	2-3	weeks,	ATOs	should	appear	round,	white,	and	with	a	smooth,	shiny	surface.		
- If	the	ATOs	are	maintained	in	culture	for	prolonged	periods	(>	10	weeks),	a	film-like	ring	of	cells	might	
be	 seen	 around	 the	 ATO.	 The	 ATO	 structure	 can	 also	 become	more	 watery	 and	 translucent.	 This	
should	not	affect	the	differentiation	or	viability	of	the	cells.		
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Flow	cytometric	analysis:		
- ATO	 cell	 phenotypes,	 differentiation	 kinetics,	 and	 cell	 yields	 are	 extensively	 characterized	 in	 the	
accompanying	article.	A	 list	of	monoclonal	antibodies	used	 for	standard	 flow	cytometric	analysis	of	
ATOs	is	listed	in	the	Online	Methods	section	of	the	accompanying	article.	
	
- Flow	cytometric	 analysis	 of	ATO	 cells	 should	 include	at	minimum	a	 viability	dye	 (e.g.	DAPI)	 for	 the	
exclusion	 of	 dead	 cells,	 and	 staining	 for	 either	 human	 CD45	 or	 mouse	 CD29	 to	 gate	 on	 human	
hematopoietic	cells	or	gate	out	MS5-hDLL1	cells,	respectively.	This	is	particularly	important	if	FITC	or	
eGFP	are	used	 in	 the	 study,	 as	MS5-hDLL1	 cells	express	eGFP	and	may	confound	analysis.	We	also	
highly	 recommend	 that	 labeling	 for	 human	 CD14	 be	 included	 in	 any	 analysis	 panel	 to	 gate	 out	
monocytes/macrophages—while	 rare	 in	 ATOs,	 strong	 autofluorescence	 from	 this	 population	 may	
interfere	with	downstream	analysis.	Staining	for	human	CD56	is	optional	to	gate	out	NK	cells,	which	
develop	at	low	but	variable	levels	in	ATOs	and	may	co-express	certain	T	cell	markers.	
	
- If	starting	with	CB	HSPCs	 in	ATOs,	CD4+CD5+CD3-	 immature	single	positive	(CD4ISP)	and	CD4+CD8+	
double	positive	(DP)	thymocytes	are	seen	as	early	as	2	weeks,	with	and	a	more	distinct	and	robust	DP	
population	at	3	weeks.		
	
- A	 clear	 population	 of	 CD34+	 progenitors	 should	 be	 detectable	 at	 all	 time	 points	 of	 the	 culture,	
decreasing	in	frequency	with	time.	Within	the	CD34+	population,	pro-T	cell	subsets	can	be	identified	
using	CD7	and	CD1a,	or	CD7	and	CD5,	as	described	in	the	accompanying	article.	
	
- A	clear	population	of	TCRαβ+CD3+	thymocytes	should	be	detectable	as	early	as	week	4.	At	this	point	
the	 majority	 of	 CD3+TCRαβ+	 cells	 will	 be	 DP,	 however	 progressive	 differentiation	 to	 CD8	 single	
positive	(CD8SP)	and	CD4SP	T	cells	is	seen,	typically	starting	around	week	6.	
	
- CD3+TCRαβ+CD4SP	yields	in	ATOs	generated	as	described	are	lower	than	for	CD8SP	T	cells,	and	may	
range	from	5-15%	of		CD3+TCRαβ+	T	cells	after	week	6.	
	
- Within	 the	 CD3+TCRαβ+CD8SP	 and	 CD4SP	 populations,	 immature	 naïve	 T	 cells	 with	 a	 DP-like	
phenotype	 (CD45RA-CD45RO+CD1ahigh)	 can	 be	 further	 differentiated	 from	 mature	 naïve	 T	 cells	
(CD45RA+CD45RO-CD1alo).	The	frequency	of	cells	with	the	mature	naïve	phenotype	increases	in	ATOs	
between	weeks	6-12.		
	
- Care	must	be	taken	when	analyzing	CD8+	and	CD4+	T	cells	in	ATOs,	as	it	is	insufficient	to	define	these	
populations	based	on	single	markers,	as	both	CD4ISP	and	CD8aa+	innate	lymphoid	cells	are	present	in	
ATOs	and	confound	this	analysis.	Rather,	gating	on	CD3+,	TCRαβ+,	or	both	markers	 first	will	assure	
gating	on	true	mature	T	cells.		
	
- Examination	of	total	T-lineage	cells	(CD7+CD5+)	provides	a	simple	read	out	of	T	cell	differentiation	in	
ATOs	at	any	time	point,	however	does	not	give	an	indication	as	to	T	cell	developmental	stage.	
	
- An	ATO	made	from	7500	cord	blood	HSPCs	should	give	rise	to	an	average	of	1.5	to	2x106	total	cells	at	
week	6.	Higher	cell	numbers	are	seen	with	TCR-transduced	CB	HSPCs.	The	fraction	of	total	cells	that	
are	mature	CD3+TCRαβ+CD8SP	or	CD4SP	T	cells	depends	on	the	timepoint	of	harvesting,	with	percent	
mature	cells	increasing	progressively	between	weeks	6-12.	
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